A Study of Tirzepatide (LY3298176) Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT) is an ongoing trial trying to evaluate the noninferiority or even superiority of the dual incretin, tirzepatide, in comparison to the GLP-1 Ra dulaglutide in terms of major adverse CVEs in patients with T2DM [45]. This evidence concerns the gene GCG and type 2 diabetes mellitus.